Cemiplimab vs Sasanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Cemiplimab
Marketed by Regeneron Pharmaceuticals and partners
NCT03088540 · Phase 3 · completed
This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.
Next expected readout: December 2026 · NCT06623656 (registry estimate)
Reported efficacy
Overall Survival (OS) (Up to 94 months); Progression-free Survival (PFS) Per Blinded IRC (Up to 94 months): Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) (met)
Result source: NCT03088540
Sasanlimab
Developed by Pfizer
NCT04181788 · Phase 1/2 · completed
Phase 1/2 open-label study in advanced malignancies (155 participants). The primary endpoints are dose-limiting toxicities and pharmacokinetic exposure, reported descriptively; no efficacy hypothesis was tested as a primary comparison.
Reported efficacy
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms); Phase 2: AUCτ of PF-06801591 at Steady State (Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm); Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12 (Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm): Dose-limiting toxicities in phase 1b: 0 participants in each of the four arms (sasanlimab 300 mg SC Q4W escalation and expansion, 600 mg SC Q6W escalation and expansion); no comparator arm. (not_applicable)
Result source: NCT04181788
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cemiplimab | Sasanlimab |
|---|---|---|
| PFS, median | 6.3 vs 5.3vs ChemotherapyNCT030885403 other results
| —Trial running · NCT06218069 |
| OS, median | 21.1 vs 12.9+8.2 vs placeboNCT034096143 other results
| 14.7bNCT025732591 other result
|
| ORR | 43.6% vs 22.1%+21.5 vs placeboNCT034096143 other results
| 16.4%bNCT025732593 other results
|
| Duration of response, median | 16.4 vs 7.3+9.1 vs placeboNCT034096143 other results
| —Trial running · NCT06218069 |
PFS, median
- Cemiplimab
- 6.3 vs 5.3vs ChemotherapyNCT03088540
3 other results
- 8.2 vs 5.5 NCT03409614
- 6.5 vs 6.4 NCT03409614
- 6.4 vs 6.4 NCT03409614
- Sasanlimab
- —Trial running · NCT06218069
OS, median
- Cemiplimab
- 21.1 vs 12.9+8.2 vs placeboNCT03409614
3 other results
- 23.4 vs 13.7 NCT03088540
- 15.9 vs 13.9 NCT03409614
- 20.1 vs 13.9 NCT03409614
- Sasanlimab
- 14.7bNCT02573259
1 other result
- 10.9 NCT02573259
ORR
- Cemiplimab
- 43.6% vs 22.1%+21.5 vs placeboNCT03409614
3 other results
- 42.3% vs 21.4% NCT03088540
- 40.7% vs 28.3% NCT03409614
- 36.7% vs 28.3% NCT03409614
- Sasanlimab
- 16.4%bNCT02573259
3 other results
- 18.4% NCT02573259
- 19.4% NCT02573259
- 21.1% NCT02573259
Duration of response, median
- Cemiplimab
- 16.4 vs 7.3+9.1 vs placeboNCT03409614
3 other results
- 24.1 vs 5.9 NCT03088540
- 7.8 vs 6.2 NCT03409614
- 15.9 vs 6.2 NCT03409614
- Sasanlimab
- —Trial running · NCT06218069
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Cemiplimab: 4 of 4 rows · Sasanlimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cemiplimab | Sasanlimab |
|---|---|---|
| Dropout rate | 79%Cemiplimaba NCT03088540 · Phase 3 show 10 more results—Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 90.7%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 91.7%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 90.1%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 0%30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 0%10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | n/a: no completion milestone600 mg SC Q6Wa NCT04181788 · Phase 1/2 show 12 more resultsn/a: no completion milestone600 mg SC Q6W NCT04181788 · Phase 1/2 n/a: no completion milestone600 mg SC Q6W NCT04181788 · Phase 1/2 n/a: no completion milestone300 mg SC Q4W NCT04181788 · Phase 1/2 n/a: no completion milestone300 mg SC Q4W NCT04181788 · Phase 1/2 n/a: no completion milestone300 mg SC Q4W NCT04181788 · Phase 1/2 86.7%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 85.3%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 87.2%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 85.7%10 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 75%3 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 100%1 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 50%0.5 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 0.3%Cemiplimaba NCT03088540 · Phase 3 show 10 more results—Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 0%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 0%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 0.3%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination —30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination —10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | 16.7%600 mg SC Q6Wa NCT04181788 · Phase 1/2 show 12 more results0%600 mg SC Q6W NCT04181788 · Phase 1/2 3.8%600 mg SC Q6W NCT04181788 · Phase 1/2 0%300 mg SC Q4W NCT04181788 · Phase 1/2 16.7%300 mg SC Q4W NCT04181788 · Phase 1/2 2.4%300 mg SC Q4W NCT04181788 · Phase 1/2 —300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence —300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence —300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence —10 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence —3 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence —1 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence —0.5 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 36.8%Cemiplimaba NCT03088540 · Phase 3 show 10 more results27.1%Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 35.2%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 35.8%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 30.4%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 33.3%30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 40%20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 23.8%20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 11.1%10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 25%3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 60%1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | 0%600 mg SC Q6Wa NCT04181788 · Phase 1/2 show 12 more results0%600 mg SC Q6W NCT04181788 · Phase 1/2 16.3%600 mg SC Q6W NCT04181788 · Phase 1/2 25%300 mg SC Q4W NCT04181788 · Phase 1/2 16.7%300 mg SC Q4W NCT04181788 · Phase 1/2 39%300 mg SC Q4W NCT04181788 · Phase 1/2 20%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 26.5%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 34.2%300 mg SC NCT02573259 · Phase 1 · registry result, not featured evidence 42.9%10 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 37.5%3 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 37.5%1 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence 50%0.5 mg/kg IV NCT02573259 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | show 10 more resultsanaemia 48.1% (placebo 39.9%) neutropenia 28.7% (placebo 12.4%) alopecia 27.8% (placebo 43.8%) NCT03409614 · Phase 3 · combination anaemia 33.9% (placebo 39.9%) nausea 28.4% (placebo 16.3%) fatigue 21.1% (placebo 8.5%) NCT03409614 · Phase 3 · combination anaemia 44.2% (placebo 39.9%) alopecia 37.5% (placebo 43.8%) nausea 25.3% (placebo 16.3%) NCT03409614 · Phase 3 · combination 30 mg/kg infusion related reaction 66.7% anaemia 33.3% abdominal pain 26.7% NCT05259696 · Phase 1/2 · registry result, not featured evidence 20 mg/kg infusion related reaction 66.7% anaemia 40% constipation 26.7% NCT05259696 · Phase 1/2 · registry result, not featured evidence 20 mg/kg in combination with cemiplimab infusion related reaction 42.9% cough 33.3% fatigue 33.3% NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 10 mg/kg infusion related reaction 55.6% fatigue 33.3% dehydration 22.2% NCT05259696 · Phase 1/2 · registry result, not featured evidence 3 mg/kg abdominal pain 25% arthralgia 25% back pain 25% NCT05259696 · Phase 1/2 · registry result, not featured evidence 1 mg/kg abdominal pain 60% nausea 60% vomiting 40% NCT05259696 · Phase 1/2 · registry result, not featured evidence | 600 mg SC Q6Wa pruritus 50% alanine aminotransferase increased 16.7% alopecia 16.7% NCT04181788 · Phase 1/2 show 12 more results600 mg SC Q6W anaemia 50% blood glucose increased 33.3% blood bilirubin increased 25% NCT04181788 · Phase 1/2 300 mg SC Q4W alanine aminotransferase increased 25% anaemia 25% aspartate aminotransferase increased 25% NCT04181788 · Phase 1/2 300 mg SC decreased appetite 46.7% nausea 40% dyspnoea 33.3% NCT02573259 · Phase 1 · registry result, not featured evidence 300 mg SC anaemia 19.1% dyspnoea 14.7% decreased appetite 13.2% NCT02573259 · Phase 1 · registry result, not featured evidence 300 mg SC anaemia 31.6% asthenia 15.8% back pain 15.8% NCT02573259 · Phase 1 · registry result, not featured evidence 10 mg/kg IV generalised oedema 57.1% constipation 42.9% aspartate aminotransferase increased 28.6% NCT02573259 · Phase 1 · registry result, not featured evidence 3 mg/kg IV generalised oedema 50% arthralgia 37.5% blood thyroid stimulating hormone increased 37.5% NCT02573259 · Phase 1 · registry result, not featured evidence 1 mg/kg IV constipation 50% decreased appetite 37.5% generalised oedema 37.5% NCT02573259 · Phase 1 · registry result, not featured evidence 0.5 mg/kg IV back pain 100% blood creatinine increased 100% constipation 100% NCT02573259 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cemiplimab
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 2 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
+ 40 further endpoints in the CSV export.
Sasanlimab
show 3 more results
show 9 more results
show 2 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Sasanlimab's landscape